Orforglipron
Investigational. This is an investigational compound and is not approved for marketing. Material and development services are offered only to qualified entities for research and pharmaceutical development, subject to applicable law.
Orforglipron is an investigational oral small-molecule GLP-1 receptor agonist under clinical development for type 2 diabetes and obesity. BOOKPHARM supports orforglipron through CDMO development of the active ingredient and intermediates.
| Business line | Business model | Regulatory status |
|---|---|---|
| FDFGLP-1 & GIP actives | API + FDF CMO/Supply | CDMO |
| APIGLP-1 & GIP actives | CDMO/CMO of API+intermediates | NDC |
Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied. Availability is subject to regulatory approval in the buyer's jurisdiction.
Before you request a quote
What is the minimum order quantity?
It depends on the product and supply format. Tell us your required quantity so we can confirm the available minimum in your quotation.
How long does delivery take?
Lead times vary by product, order size and destination. We ship to qualified B2B buyers worldwide, including the US, Brazil, Mexico and other Latin American markets, subject to local regulatory requirements. We confirm timing in the quotation.
What payment terms are available?
We can discuss flexible B2B payment arrangements. The method and terms are agreed for each order and confirmed in the quotation.
What documentation can you provide?
Available quality and regulatory documents depend on the product and manufacturer. Tell us what your team needs, and we will confirm the documents available for review.